Abbott gains after upcoming baby formula case thrown out
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 02 2025
0mins
Source: SeekingAlpha
Abbott Laboratories Legal Ruling: A judge ruled in favor of Abbott Laboratories, granting their request for summary judgment in a trial concerning claims that their baby formula causes necrotizing enterocolitis (NEC), although the ruling does not dismiss all related litigation.
Ongoing Litigation: Over 1,000 lawsuits have been filed against Abbott and Reckitt Benckiser regarding the safety of infant formulas, with plaintiffs alleging that cow's milk-based formulas are linked to NEC.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 148.11 USD with a low forecast of 136.00 USD and a high forecast of 169.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 108.610
Low
136.00
Averages
148.11
High
169.00
Current: 108.610
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
